Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
Nematollah Gheibi, Morteza Shakhsi Niaee, Peyman Namdar, Abbas Allami, Leila Zolghadr, Amir Javadi, Amin Karampour, Mehran Varnaseri, Behzad Bijani, Fatemeh Cheraghi, Yazdan Naderi, Fatemeh Amini, Masoumeh Karamyan, Mohammadjafar Yadyad, Ramin Jamshidian
Asian Pacific Journal of Tropical Medicine, doi:10.4103/1995-7645.318304
To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin (200 µg/kg), three low interval doses of ivermectin (200, 200, 200 µg/kg), single dose ivermectin (400 µg/kg), and three high interval doses of ivermectin (400, 200, 200 µg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O 2 saturation duration, and hematological variables of blood samples were analyzed. Results: A total of 16.7% (5/30) and 20.0% (6/30) patients died in arms treated with hydroxychloroquine 200 mg twice per day and placebo plus hydroxychloroquine 200 mg twice per day, respectively, and a reduction in mortality rate in patients receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for arms 1-4 were observed. Risk of mortality was also decreased about 15% in the ivermectin treated arms. Conclusions: Ivermectin as an adjunct reduces the rate of mortality, time of low O 2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parameters shows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19.
Conflict of interest statement We declare that we have no conflict of interest.
Authors' contributions GN, NMS, NP, AA designed the study. BB,VM,YYMJ, KA, FA, KM and JR were responsible for overall data collection and clinical studies. ZL, JA, AA conducted data analysis and interpretation. ZL drafted the first manuscript and has designed Figure1. GN and AA revised the manuscript critically. NY and ZL were in charge of drug formulation. All authors read and approved the final manuscript. NMS,GN,CHF and NP supervised the project.
References
Anton, Haas, Arlett, Weise, Balabanov et al., Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective, Clin Pharmacol Ther
Azeem, Ashraf, Rasheed, Anjum, Hameed, Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus, Pak J Pharm Sci
Baraka, Mahmoud, Marschke, Geary, Homeida et al., Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus, Eur J Clin Pharmacol
Barrows, Campos, Powell, Prasanth, Schott-Lerner et al., A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N Engl J Med
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Campbell, Benz, Ivermectin: A review of efficacy and safety, J Vet Pharmacol Ther
Camprubí, Almuedo-Riera, Martí-Soler, Soriano, Hurtado et al., Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PloS One
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
De Oliveira, Rocha, Paluch, Costa, Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening, J Biomol Struct Dyn,
doi:10.1080/07391102.2020.1772885Fox, Mechanism of action of hydroxychloroquine as an antirheumatic drug, Semin Arthritis Rheum
Frieman, Yount, Heise, Kopecky-Bromberg, Palese et al., Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane, J Virol
Gillenwater, Rahaghi, Hadeh, Remdesivir for the treatment of Covid-19 -Preliminary report, N Engl J Med
Heidary, Gharebaghi, Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot
Ignatius, Wang, Karaba, Robinson, Avery et al., Tocilizumab for the treatment of covid-19 among hospitalized patients: A matched retrospective cohort analysis, Open Forum Infect Dis
Kelleni, Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management, Pharmacol Res
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3 737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3 737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, Vivo
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol
Li, Wang, Xu, Cao, Potential antiviral therapeutics for 2019 Novel Coronavirus, Zhonghua Jie He He Hu Xi Za Zhi
Lifschitz, Virkel, Sallovitz, Sutra, Galtier et al., Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle, Vet Parasitol
Lundberg, Pinkham, Baer, Amaya, Narayanan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, Antiviral Res
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of Ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial, JAMA
Mastrangelo, Pezzullo, Burghgraeve, Kaptein, Pastorino et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug, J Antimicrob Chemother
Patrì, Fabbrocini, Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, J Am Acad Dermatol
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in covid nineteen study, Chest
Risch, Early outpatient treatment of symptomatic, high-risk covid-19 patients that should be ramped up immediately as key to the pandemic crisis, Am J Epidemiol
Sahu, Mishra, Raturi, Lal, Current Perspectives of convalescent plasma therapy in COVID-19, Acta Biomed
Sahu, Siddiqui, Cerny, Mesenchymal stem cells in COVID-19: A journey from bench to bedside, Lab Med
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther
Sharun, Dhama, Patel, Pathak, Tiwari et al., Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob
Sharun, Shyamkumar, Aneesha, Dhama, Pawde et al., Current therapeutic applications and pharmacokinetic modulations of ivermectin, Vet World
Shouman, Use of ivermectin as a prophylactic option in asymptomatic family close contact for patient with COVID-19
Silva, On the possibility of interrupting the coronavirus (COVID-19) epidemic based on the best available scientific evidence, Rev Bras Epidemiol
Singh, Singh, Shaikh, Singh, Misra, Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries, Diabetes Metab Syndr
Smit, Ochomo, Waterhouse, Kwambai, Abong et al., Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL), Clin Pharmacol Ther
Sturrock, Chevassut, Chloroquine and COVID-19: A potential game changer?, Clin Med (Lond)
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin 毩 / 毬 -mediated nuclear, Biochem J
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebocontrolled, multicentre trial, Lancet
Wassenaar, Zou, 2019_nCoV/SARS-CoV-2: Rapid classification of betacoronaviruses and identification of Traditional Chinese Medicine as potential origin of zoonotic coronaviruses, Lett Appl Microbiol
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA
Yamasmith, Mairiang, Tanrumluk, Suputtamongkol, Saleh-Arong, Efficacy and safety of ivermectin against dengue infection: A phase 栿 , randomized, double-blind, placebo-controlled trial
Yu, Wang, Li, Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19, Medrxiv,
doi:10.11001/2020.04.27.20073379
